Bioequivalence of 5 Tablets of 100 Milligrams (mg) Versus 2 Tablets of 250 mg Tablet Formulation 3 (TF3) of Tepotinib
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This study will investigate the bioequivalence of the 100 mg and 250 mg dose strengths of
tepotinib TF3 when administered at the same dose under fasted condition.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany